To the full analysis
STAAR Surgical stock: growth
STAASTAAR Surgical reported $239.44M in revenue for fiscal 2025, down 23.7% on the prior year, up 11.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
7.9%
per year from 2006 to 2025, per share 4.1%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 7.9% | 12.0% | 7.9% |
| Revenue per share | 6.1% | 9.2% | 4.1% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $56.28M | −$15.04M | −$9.43M |
| 2007 | $59.36M | −$16M | −$11.88M |
| 2008 | $74.89M | −$23.2M | −$9.32M |
| 2009 | $75.35M | −$6.2M | $841K |
| 2010 | $54.96M | $53K | −$4.74M |
| 2011 | $62.77M | $1.35M | $4.38M |
| 2012 | $63.78M | −$1.76M | $906K |
| 2013 | $72.22M | $398K | −$96K |
| 2014 | $74.99M | −$8.39M | −$12.01M |
| 2015 | $77.12M | −$6.53M | −$4.21M |
| 2016 | $82.43M | −$12.13M | −$2.16M |
| 2017 | $90.61M | −$2.14M | $1.81M |
| 2018 | $123.95M | $4.97M | $10.52M |
| 2019 | $150.19M | $14.05M | $15.62M |
| 2020 | $163.46M | $5.91M | $12.55M |
| 2021 | $230.47M | $27.51M | $30.32M |
| 2022 | $284.39M | $39.67M | $17.61M |
| 2023 | $322.42M | $21.35M | −$3.59M |
| 2024 | $313.9M | −$20.21M | −$7.67M |
| 2025 | $239.44M | −$80.45M | −$40.05M |
Revenue by region
Where STAAR Surgical Company generates its revenue.
- China37%
- Japan19%
- United States6%
- Other38%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2016 | 2017 | 2018 | Share 2018 | |
|---|---|---|---|---|
| China | $16.02M | $23.88M | $46.07M | 37.2% |
| Japan | $17.33M | $17.42M | $23.15M | 18.7% |
| United States | $9.86M | $7.89M | $7.32M | 5.9% |
| Other | $39.23M | $41.41M | $47.42M | 38.3% |
| Total revenue | $82.43M | $90.61M | $123.95M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 2 Jan 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 21 Feb 2025)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.